Andrea Apolo, M.D.
@apolo_andrea
Medical Oncologist, Senior Investigator, Chief, #BladderCancer Section, #GenitourinaryTumors, NCI, NIH #RareTumors #PatientAdvocate, Latina Views are my own
ID: 2419804603
31-03-2014 01:47:20
10,10K Tweet
7,7K Followers
2,2K Following
What an amazing #BCANTT24 it was! Thx Eugene Pietzak Stephanie Chisolm, PhD Rebecca Johnson, SC members, co-chairs, speakers, pt advocates & attendees for a fantastic meeting. It was all about patients from beginning to end! Looking forward to working w/ Max Kates for planning #BCANTT25
What a journey! Thanks Ravi A Madan M.D. and William Douglas Figg, Sr for the support and NCI Center for Cancer Research and @gulleyj1
Urachal and Nonurachal Adenocarcinomas of the Urinary Bladder: A Comprehensive Genomic Profiling Study | JCO Precision Oncology ASCO | Antonio Cigliola Chiara Mercinelli Valentina Tateo Brigida Maiorano Università Vita-Salute San Raffaele Ospedale San Raffaele UroToday.com Medscape Foundation Medicine Petros Grivas Ashish M. Kamat, MD, MBBS
Toni Choueiri, MD NEJM U.S. FDA ESMO - Eur. Oncology Guillermo de Velasco Mauricio Burotto Cris Roberto Iacovelli Brian Rini, MD Maria Carmen De Santis Fabio Schutz Laurence Albiges Charles Swanton Congrats Toni Choueiri, MD Tom Powles Laurence Albiges Brian Rini, MD and the team for this stupendous work leading to approval of belzutifan for our patients with mccRCC #kidneycancer Kidney Cancer KidneyCAN
Barcelona 🇪🇸 #ESMO24 We Are There🚨 For Colleagues....By Colleagues #OncoAlertAF Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Biagio Ricciuti, MD PhD Emre Yekedüz Hidehito HORINOUCHI Fadi Haddad, MD Dr. Iván R. González Al-Ola A Abdallah MD (USMIRC) Jose Fernando Moura, PhD Elisa Agostinetto Elisabetta Bonzano MD, PhD Eric K. Singhi, MD Bárbara Melão, MD
TROPHY-U-01 Cohort 2: Sacituzumab Govitecan achieved an ORR of 32% in cisplatin-ineligible metastatic urothelial cancer. Median PFS was 5.6 months. Main toxicities: neutropenia (34%), anemia (24%), and diarrhea (16%). #cancer #oncology OncoAlert Scott Tagawa Cora Sternberg
Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma. What is most important to patients regarding their experiences of disease burden and treatment #BladderCancer Nicholas Simon link.springer.com/article/10.100…
Just in Annals of Oncology 👉on the heels of the recent approval of belzutifan in mRCC #kidneycancer , herein we show in a ph2 randomized trial👉more belzutifan (200 mg vs 120 mg QD) was not better👇Link: tinyurl.com/nrsxp8s4 UroToday.com OncoAlert KidneyCAN Huntsman Cancer Institute
Dear Colleagues, The OncoAlert 🚨Network Presents OUR Picks of TOP 🔟 #LungCancer 🫁Abstracts to be Presented at #ESMO24 This List Curated by: #OncoAlertAF Leads Hidehito HORINOUCHI 🇯🇵 Biagio Ricciuti, MD PhD 🇺🇸 Eric K. Singhi, MD 🇺🇸 Gil Morgan, MD 🇺🇸 With our Distinguished OncoAlert 🚨Faculty
Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…
Dr. Scott Dehm Scott Dehm Masonic Cancer Center, University of Minnesota discusses his team’s research on the biology of lethal castration resistance in #ProstateCancer including emerging underlying #genomic 🧬 understanding NCI CCR GU Malignancies GU Seminar Series NCI Center for Cancer Research National Cancer Institute